ICU Medical, Inc. (NASDAQ:ICUI) Receives Average Recommendation of “Moderate Buy” from Brokerages

ICU Medical, Inc. (NASDAQ:ICUI) has received an average recommendation of “Moderate Buy” from the five brokerages that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, two have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $175.6667.

A number of brokerages have commented on ICUI. Weiss Ratings reiterated a “sell (d-)” rating on shares of ICU Medical in a report on Wednesday, October 8th. Wall Street Zen cut ICU Medical from a “buy” rating to a “hold” rating in a research note on Sunday. Piper Sandler increased their price target on ICU Medical from $153.00 to $172.00 and gave the company an “overweight” rating in a report on Friday, November 7th. Finally, KeyCorp raised their price objective on ICU Medical from $173.00 to $175.00 and gave the company an “overweight” rating in a research note on Friday, November 7th.

Insiders Place Their Bets

In related news, Director Elisha W. Finney sold 1,285 shares of ICU Medical stock in a transaction on Tuesday, November 11th. The shares were sold at an average price of $140.42, for a total value of $180,439.70. Following the completion of the sale, the director owned 3,995 shares in the company, valued at approximately $560,977.90. The trade was a 24.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Virginia Ruth Sanzone sold 930 shares of the stock in a transaction on Tuesday, November 11th. The shares were sold at an average price of $142.34, for a total transaction of $132,376.20. Following the transaction, the vice president owned 5,456 shares in the company, valued at $776,607.04. This trade represents a 14.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 1.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On ICU Medical

Several large investors have recently modified their holdings of ICUI. Arizona State Retirement System grew its position in shares of ICU Medical by 1.3% in the 3rd quarter. Arizona State Retirement System now owns 6,903 shares of the medical instruments supplier’s stock worth $828,000 after acquiring an additional 91 shares in the last quarter. Moody National Bank Trust Division lifted its stake in ICU Medical by 0.9% during the second quarter. Moody National Bank Trust Division now owns 10,751 shares of the medical instruments supplier’s stock worth $1,421,000 after purchasing an additional 93 shares during the last quarter. Smartleaf Asset Management LLC boosted its holdings in ICU Medical by 11.6% in the second quarter. Smartleaf Asset Management LLC now owns 969 shares of the medical instruments supplier’s stock worth $128,000 after purchasing an additional 101 shares during the period. BNP Paribas Financial Markets boosted its holdings in ICU Medical by 4.5% in the second quarter. BNP Paribas Financial Markets now owns 2,459 shares of the medical instruments supplier’s stock worth $325,000 after purchasing an additional 107 shares during the period. Finally, Thrivent Financial for Lutherans increased its stake in ICU Medical by 0.6% during the second quarter. Thrivent Financial for Lutherans now owns 18,098 shares of the medical instruments supplier’s stock valued at $2,392,000 after purchasing an additional 114 shares during the last quarter. Institutional investors own 96.10% of the company’s stock.

ICU Medical Stock Performance

ICU Medical stock opened at $152.99 on Monday. The firm has a market capitalization of $3.78 billion, a PE ratio of -493.50 and a beta of 0.80. ICU Medical has a one year low of $107.00 and a one year high of $175.51. The stock’s 50 day moving average price is $143.10 and its 200 day moving average price is $131.46. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.19 and a current ratio of 2.45.

ICU Medical (NASDAQ:ICUI) last posted its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $2.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.43 by $0.60. ICU Medical had a negative net margin of 0.32% and a positive return on equity of 7.71%. The company had revenue of $533.30 million for the quarter, compared to analyst estimates of $511.46 million. During the same quarter last year, the firm posted $1.59 earnings per share. The business’s quarterly revenue was down 8.9% on a year-over-year basis. ICU Medical has set its FY 2025 guidance at 7.350-7.650 EPS. As a group, sell-side analysts expect that ICU Medical will post 4.11 EPS for the current fiscal year.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.